40 results
8-K
EX-99.1
IMUX
Immunic Inc
20 Oct 20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
7:19am
to accelerate the development of innovative treatments against coronavirus and other severe diseases faced by our society.”
“The funding commitment … to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combating infectious diseases
8-K
EX-99.1
IMUX
Immunic Inc
15 Apr 19
Immunic Therapeutics and Vital Therapies Complete Transaction
4:30pm
, we have a strong cash position, which should allow us to reach a number of important inflection points in 2020.”
The company’s innovative pipeline
8-K
EX-99.1
IMUX
Immunic Inc
16 Oct 15
Vital Therapies provides corporate update and announces date of third quarter 2015 financial results
12:00am
in the development of an innovative lifesaving therapy. The Board considers it to be in the interests of all shareholders to provide additional incentives
8-K
EX-10.3
IMUX
Immunic Inc
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
, Confidentiality
Section 9
Miscellaneous
RECITALS
WHEREAS, 4SC is an innovative biotech company with a strong focus on research and development
DEF 14A
IMUX
Immunic Inc
7 Oct 15
Definitive proxy
12:00am
that develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. From November 2002 to April 2005, Mr. Bienaimé served … biopharmaceutical company focused on advancing innovative therapies for vascular diseases, since September 2012. Dr. Nash earned a B.A. in biology from
8-K
83x1e6 zrvfv
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
10-K
o91hgzgorqdoo
20 Mar 15
Annual report
12:00am
424B5
qsev idyrl3o7
27 Apr 20
Prospectus supplement for primary offering
12:00am
424B5
ti8f9rfsmnfo1d
11 Jun 20
Prospectus supplement for primary offering
4:10pm
424B5
kxabh8ag
9 Jun 20
Prospectus supplement for primary offering
9:56pm
424B4
n02tlc iu
3 Oct 14
Prospectus supplement with pricing info
12:00am
424B4
e5a4bx1cmh p5onnui
17 Apr 14
Prospectus supplement with pricing info
12:00am